Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
By: GlobeNewswire - 03 Oct 2022 | Back to overview list |
|
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 242,000 shares of its common stock to seven employees outside Cullinan Oncology, Inc.’s 2021 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individuals entering into employment with Cullinan, in accordance with Nasdaq Listing Rule 5635(c)(4). Seven employees received options to purchase an aggregate of 242,000 shares of Cullinan’s common stock on October 3, 2022 and have an exercise price of $12.83, which is equal to the closing price of Cullinan’s common stock on October 3, 2022. Each option has a ten-year term and vests over four years, with 25 percent of the original number of shares underlying each option vesting on the one-year anniversary of the vesting commencement date and then in equal installments for 36 months thereafter, subject to the employee's continued service with Cullinan through the applicable vesting dates. About Cullinan Oncology Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter. Contacts Media |
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |